Cite
HARVARD Citation
Badrising, S. et al. (2014). Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer. 120 (7), pp. 968-975. [Online].